• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday

    11/8/22 5:00:19 AM ET
    $ACMR
    $ACOR
    $ADPT
    $AFMD
    Industrial Machinery/Components
    Technology
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ACMR alert in real time by email

    Gainers

    • Digital World Acquisition Corp. (NASDAQ:DWAC) shares jumped 66.5% to settle at $29.10 on Monday amid recent reports suggesting Donald Trump could announce a 2024 presidential run this week. Digital World Acquisition Corp is the business combination partner of Trump Media & Technology Group.
    • Arqit Quantum Inc. (NASDAQ:ARQQ) gained 46.9% to settle at $8.21.
    • Oyster Point Pharma, Inc. (NASDAQ:OYST) jumped 38.6% to close at $11.57 after the company announced it will be acquired by Viatris for $11 per share.
    • Phunware, Inc. (NASDAQ:PHUN) shares rose 38.3% to close at $1.66 following recent reports Donald Trump could soon announce a 2024 presidential run. The company was involved in the creation of the Trump 2020 mobile app.
    • Veru Inc. (NASDAQ:VERU) shares surged 34.5% to settle at $14.44 following publication of briefing documents ahead of the Nov. 9 FDA Adcom meeting for its COVID-19 treatment candidate.
    • Monopar Therapeutics Inc. (NASDAQ:MNPR) gained 32.6% to settle at $3.95.
    • Funko, Inc. (NASDAQ:FNKO) rose 28.7% to close at $10.19.
    • ACM Research, Inc. (NASDAQ:ACMR) jumped 27.7% to close at $8.44 after Jefferies upgraded the stock from Underperform to Hold.
    • GigaCloud Technology Inc. (NASDAQ:GCT) shares gained 26.6% to close at $5.90. GigaCloud Technology, last month, unveiled its new private domain feature for sellers on its B2B GigaCloud Marketplace.
    • Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) jumped 25.9% to close at $39.73 after the company reported better-than-expected Q3 results.
    • Tupperware Brands Corporation (NYSE:TUP) gained 25.9% to settle at $5.06. Richard Goudis, Executive Vice Chair at Tupperware Brands, reported a large insider buy on November 7, according to a new SEC filing.
    • AGBA Acquisition Limited (NASDAQ:AGBA) surged 25.8% to close at $9.45.
    • Jianzhi Education Technology Group Company Limited (NASDAQ:JZ) gained 24.7% to close at $1.82.
    • Dragon Victory International Limited (NASDAQ:LYL) gained 24.3% to close at $0.5601 on Monday.
    • Aptinyx Inc. (NASDAQ:APTX) rose 24% to settle at $0.3266.
    • First High-School Education Group Co., Ltd. (NYSE:FHS) surged 23.1% to settle at $0.2760.
    • Affimed N.V. (NASDAQ:AFMD) surged 22.6% to close at $2.39. Affimed issued data update from two Phase 1/2a trials with innate cell engager AFM24 in solid tumor patients at 37th SITC Annual Meeting.
    • Camber Energy, Inc. (NYSE:CEI) gained 21.9% to close at $0.1513.
    • Senmiao Technology Limited (NASDAQ:AIHS) surged 19.8% to settle at $1.05.
    • Certara, Inc. (NASDAQ:CERT) climbed 19.6% to close at $12.73 after Arsenal Capital Partners increased its investment in the company with a $449 million stock purchase.
    • Remark Holdings, Inc. (NASDAQ:MARK) rose 19.6% to close at $0.3194.
    • Agile Therapeutics, Inc. (NASDAQ:AGRX) gained 19.4% to settle at $0.3190 following upbeat Q3 results.
    • Impac Mortgage Holdings, Inc. (NYSE:IMH) gained 19.2% to close at $0.3197.
    • Oncolytics Biotech Inc. (NASDAQ:ONCY) jumped 19.1% to close at $1.50. Oncolytics Biotech reported interim results from Phase 1/2 Goblet study showing a 70% objective response rate in pancreatic cancer at the SITC Annual Meeting. The company also posted a Q3 loss of $0.08 per share.
    • Faraday Future Intelligent Electric Inc. (NASDAQ:FFIE) rose 18.7% to close at $0.6896.
    • Glatfelter Corporation (NYSE:GLT) gained 18.4% to settle at $3.67. The company recently posted downbeat quarterly results.
    • Bandwidth Inc. (NASDAQ:BAND) jumped 17.9% to close at $20.26. Bandwidth recently reported better-than-expected Q3 sales results.
    • comScore, Inc. (NASDAQ:SCOR) jumped 17.7% to close at $1.20.
    • Syneos Health, Inc. (NASDAQ:SYNH) gained 16.7% to $30.00. The stock may be rebounding after falling last week following worse-than-expected Q3 results and reduced FY22 revenue guidance.
    • Spirit AeroSystems Holdings, Inc. (NYSE:SPR) gained 16.2% to close at $27.22 after Wolfe Research upgraded the stock from Underperform to Peer Perform. The company also announced a private offering of $800 million of senior secured first lien notes due 2029.
    • HUTCHMED (China) Limited (NYSE:HCM) jumped 15.8% to close at $10.26.
    • Napco Security Technologies, Inc. (NASDAQ:NSSC) gained 14.2% to close at $28.20 following strong Q1 results.
    • GDS Holdings Limited (NASDAQ:GDS) climbed 13.8% to close at $10.89.
    • Viatris Inc (NASDAQ:VTRS) gained 13.1% to close at $10.97 after the company announced it will acquire Oyster Point Pharma.
    • Mondee Holdings, Inc. (NASDAQ:MOND) jumped 12.7% to close at $10.03.
    • SmileDirectClub, Inc. (NASDAQ:SDC) climbed 12.4% to close at $0.7192.
    • SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) rose 12.4% to close at $5.27 after gaining around 8% on Friday.
    • Amarin Corporation plc (NASDAQ:AMRN) gained 12% to close at $1.31. The company recently posted downbeat quarterly sales.
    • SilverCrest Metals Inc. (NYSE:SILV) jumped 12% to settle at $6.05.
    • Triumph Bancorp, Inc. (NYSE:TBK) gained 11.8% to close at $55.18. Triumph Bancorp commenced a modified "Dutch Auction" tender offer to repurchase up to $100 million of its common stock.
    • FiscalNote Holdings, Inc. (NYSE:NOTE) surged 11.6% to settle at $5.57.
    • Affiliated Managers Group, Inc. (NYSE:AMG) climbed 11.4% to close at $138.00 after the company reported better-than-expected Q3 EPS and sales results. The company also increased its buyback to a total of 5.8 million shares of common stock.
    • bluebird bio, Inc. (NASDAQ:BLUE) gained 11.1% to close at $6.81 as the company posted a narrower quarterly loss
    • Comstock Resources, Inc. (NYSE:CRK) rose 10% to close at $20.28. The company recently posted upbeat Q3 results.
    • Millicom International Cellular S.A. (NASDAQ:TIGO) rose 9.4% to close at $12.91. Atlas Investissement confirmed that it acquired a 7% interest in Millicom.
    • Selina Hospitality PLC (NASDAQ:SLNA) shares gained 7.5% to close at $3.88 after dipping over 19% on Friday.
    • Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) rose 5.8% to close at $1.63. Sonnet BioTherapeutics recently announced the safety profile of SON-1010. Five of the six patients had stable disease at the first follow-up scan, with one patient progressing who is now off study.

     


    Losers

    • Huadi International Group Co., Ltd. (NASDAQ:HUDI) shares tumbled 91.2% to close at $15.81 on Monday after the company reported pricing of $25 million registered direct offering.
    • Bio-Path Holdings, Inc. (NASDAQ:BPTH) dropped 46% to settle at $1.5401.
    • Bio-Path Holdings reported a $2 million registered direct offering and concurrent private placement.
    • Inhibikase Therapeutics, Inc. (NYSE:IKT) fell 41.1% to close at $0.4550 after the company announced an FDA clinical hold on its IkT-148009 programs.
    • Verve Therapeutics, Inc. (NASDAQ:VERV) fell 30.5% to close at $21.75 after the company reported its VERVE-101 IND application was placed on hold by the FDA. The company also reported Q3 earnings results.
    • Sentage Holdings Inc. (NASDAQ:SNTG) shares fell 24.7% to settle at $3.08 after jumping 35% on Friday.
    • Digital Brands Group, Inc. (NASDAQ:DBGI) dipped 24.7% to close at $6.61.
    • Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) fell 24% to settle at $0.6864.
    • Akerna Corp. (NASDAQ:KERN) fell 21.7% to close at $0.0790. Akerna will effect a 20-for-1 reverse stock split of its shares of common stock.
    • Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) dropped 20.1% to settle at $4.45. Concert Pharmaceuticals posted a Q3 loss of $0.58 per share.
    • Ucommune International Ltd (NASDAQ:UK) dipped 19.3% to close at $1.8399.
    • Acorda Therapeutics, Inc. (NASDAQ:ACOR) dropped 18.7% to settle at $0.6326. Acorda Therapeutics recently posted a Q3 loss of $0.55 per share.
    • Landos Biopharma, Inc. (NASDAQ:LABP) fell 18.6% to close at $0.2570.
    • Satixfy Communications Ltd. (NYSE:SATX) shares fell 18.5% to close at $10.34 after jumping 65% on Friday.
    • Ritchie Bros. Auctioneers Incorporated (NYSE:RBA) fell 17.7% to close at $51.29 after the company announced it will acquire IAA in a stock and cash transaction valued at roughly $7.3 billion.
    • Carvana Co. (NYSE:CVNA) dipped 15.6% to close at $7.39 on continued weakness after the company reported worse-than-expected Q3 financial results last Thursday. The company reported a year-over-year decrease in both revenue and retail units sold.
    • Adaptive Biotechnologies Corporation (NASDAQ:ADPT) dropped 14.7% to close at $7.58. Morgan Stanley maintained Adaptive Biotechnologies with an Equal-Weight and lowered the price target from $17 to $16.
    • Jumia Technologies AG (NYSE:JMIA) fell 14.3% to close at $4.20 after the company announced its co-CEOs will step down.
    • WeTrade Group, Inc. (NASDAQ:WETG) fell 13.9% to close at $1.24.
    • LSB Industries, Inc. (NYSE:LXU) fell 13.8% to settle at $14.30 after the company announced a secondary offering of 14.35 million shares of common stock by a selling stockholder with the company repurchasing 3.5 million of the shares.
    • Cepton, Inc. (NASDAQ:CPTN) fell 13% to close at $1.94.
    • Aerovate Therapeutics, Inc. (NASDAQ:AVTE) dipped 12.8% to settle at $17.86.
    • Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) fell 12.5% to close at $2.86.
    • Biora Therapeutics, Inc. (NASDAQ:BIOR) dipped 12.1% to close at $0.2891. Biora Therapeutics announced a $9.75 million direct offering.
    • Mersana Therapeutics, Inc. (NASDAQ:MRSN) dropped 11.9% to settle at $6.64 after the company reported worse-than-expected Q3 EPS and sales results.
    • Quanergy Systems, Inc. (NYSE:QNGY) shares fell 11.7% to close at $0.7353. Quanergy Systems recently priced its $16.7 million offering.
    • Beam Therapeutics Inc. (NASDAQ:BEAM) dropped 11.4% to close at $37.91 after the company reported a wider Q3 loss.
    • Ventyx Biosciences, Inc. (NASDAQ:VTYX) declined 10.9% to settle at $26.04. Ventyx Biosciences recently posted a Q3 loss of $0.59 per share.
    • Redfin Corporation (NASDAQ:RDFN) fell 9.7% to close at $3.63 after Oppenheimer downgraded the stock from Perform to Underperform.
    • Arrival (NASDAQ:ARVL) fell 9.5% to close at $0.5911.
    • First Watch Restaurant Group, Inc. (NASDAQ:FWRG) declined 8.2% to close at $14.86 after the company posted Q3 results.
    • Ruth's Hospitality Group, Inc. (NASDAQ:RUTH) declined 8.1% to close at $17.43. Raymond James downgraded Ruth's Hospitality Group from Strong Buy to Market Perform.
    • FAT Brands Inc. (NASDAQ:FAT) shares fell 6.1% to settle at $7.23. FAT Brands announced withdrawal of proposed common stock offering.

     

    Get the next $ACMR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACMR
    $ACOR
    $ADPT
    $AFMD

    CompanyDatePrice TargetRatingAnalyst
    Certara Inc.
    $CERT
    2/27/2026$10.00Buy → Hold
    Craig Hallum
    Beam Therapeutics Inc.
    $BEAM
    2/20/2026$74.00Buy
    Canaccord Genuity
    Millicom International Cellular S.A.
    $TIGO
    2/11/2026$43.00Sector Perform → Sector Underperform
    Scotiabank
    Viatris Inc.
    $VTRS
    2/9/2026$18.00Neutral → Buy
    UBS
    Jumia Technologies AG
    $JMIA
    2/6/2026$18.00Overweight
    Cantor Fitzgerald
    Bandwidth Inc.
    $BAND
    1/23/2026$20.00Buy
    B. Riley Securities
    Inhibikase Therapeutics Inc.
    $IKT
    1/21/2026$6.00Buy
    BofA Securities
    Viatris Inc.
    $VTRS
    1/16/2026$15.00Hold → Buy
    Argus
    More analyst ratings

    $ACMR
    $ACOR
    $ADPT
    $AFMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Pisano Wayne bought $25,338 worth of shares (30,000 units at $0.84), increasing direct ownership by 6% to 492,414 units (SEC Form 4)

    4 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)

    2/13/26 7:00:29 AM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Kelly Jared bought $29,521 worth of shares (35,100 units at $0.84), increasing direct ownership by 47% to 109,000 units (SEC Form 4)

    4 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)

    2/13/26 7:00:32 AM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VP, Product Development Hagerman Allison bought $8,298 worth of shares (10,000 units at $0.83), increasing direct ownership by 10% to 115,059 units (SEC Form 4)

    4 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)

    2/13/26 7:00:25 AM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACMR
    $ACOR
    $ADPT
    $AFMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive VP of Engineering Carrieri Michael exercised 10,000 shares at a strike of $22.50 and covered exercise/tax liability with 6,651 shares, increasing direct ownership by 14% to 26,610 units (SEC Form 4)

    4 - NAPCO SECURITY TECHNOLOGIES, INC (0000069633) (Issuer)

    2/27/26 4:02:09 PM ET
    $NSSC
    Telecommunications Equipment
    Telecommunications

    President Ciaramella Giuseppe exercised 35,000 shares at a strike of $17.00 and sold $1,120,042 worth of shares (35,000 units at $32.00) (SEC Form 4)

    4 - Beam Therapeutics Inc. (0001745999) (Issuer)

    2/26/26 4:05:04 PM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Aurentz Vincent returned 255,299 shares to the company, decreasing direct ownership by 33% to 510,596 units (SEC Form 4)

    4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)

    2/24/26 8:54:26 PM ET
    $IKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACMR
    $ACOR
    $ADPT
    $AFMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Certara downgraded by Craig Hallum with a new price target

    Craig Hallum downgraded Certara from Buy to Hold and set a new price target of $10.00

    2/27/26 8:32:38 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    Canaccord Genuity initiated coverage on Beam Therapeutics with a new price target

    Canaccord Genuity initiated coverage of Beam Therapeutics with a rating of Buy and set a new price target of $74.00

    2/20/26 8:23:45 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Millicom International Cellular downgraded by Scotiabank with a new price target

    Scotiabank downgraded Millicom International Cellular from Sector Perform to Sector Underperform and set a new price target of $43.00

    2/11/26 7:50:06 AM ET
    $TIGO
    Telecommunications Equipment
    Telecommunications

    $ACMR
    $ACOR
    $ADPT
    $AFMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bandwidth Announces Partial Repurchase of 0.50% Convertible Senior Notes Due 2028

    Initially issued principal balance of $250 million notes due 2028 reduced to $150 million outstandingRALEIGH, N.C., March 2, 2026 /PRNewswire/ -- Bandwidth Inc. (NASDAQ:BAND), a leading global enterprise cloud communications company, today announced that it has entered into separate, privately negotiated repurchase agreements with a limited number of holders of its 0.50% Convertible Senior Notes due 2028 (the "2028 Notes") to repurchase (the "Repurchases") $100 million aggregate principal amount of the 2028 Notes at a discount to par value. The repurchase price payable by Bandwidth will be paid in cash.

    3/2/26 6:30:00 AM ET
    $BAND
    Computer Software: Prepackaged Software
    Technology

    Certara to Participate in Upcoming Investor Conferences

    RADNOR, Pa., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences: TD Cowen 46th Annual Health Care Conference Date and Time: Tuesday, March 3rd, 2026, at 3:10PM ET Leerink Global Healthcare Conference Date and Time: Monday, March 9th, 2026, at 8:00AM ET Barclays 28th Annual Global Healthcare ConferenceDate and Time: Tuesday, March 10th, 2026, at 1:00PM ET Live webcasts for each of the conferences will be available on Certara's investor relations website at https://ir.certara.com and will be available for replay for at least 90 day

    2/27/26 8:30:00 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    Carvana to Present at Upcoming Morgan Stanley Technology, Media & Telecom Conference

    Carvana (NYSE:CVNA), a leading e-commerce platform for buying and selling cars, today announced that Ernie Garcia, Carvana's Founder and Chief Executive Officer, will present to the investor community and host meetings at the upcoming Morgan Stanley Technology, Media & Telecom Conference. Morgan Stanley Technology, Media & Telecom Conference Presentation Date and Time: Monday, March 2, 2026, at 12:20 PM PT* *A webcast of the presentation will be accessible on the Investor Relations section of the Carvana website (https://investors.carvana.com). An archived replay of the webcast will be available following the live presentation. About Carvana Carvana's mission is to change the way pe

    2/27/26 8:00:00 AM ET
    $CVNA
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    $ACMR
    $ACOR
    $ADPT
    $AFMD
    SEC Filings

    View All

    Bandwidth Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Bandwidth Inc. (0001514416) (Filer)

    3/2/26 6:32:19 AM ET
    $BAND
    Computer Software: Prepackaged Software
    Technology

    SEC Form 144 filed by Bandwidth Inc.

    144 - Bandwidth Inc. (0001514416) (Subject)

    2/27/26 6:14:12 PM ET
    $BAND
    Computer Software: Prepackaged Software
    Technology

    SEC Form S-8 filed by Adaptive Biotechnologies Corporation

    S-8 - Adaptive Biotechnologies Corp (0001478320) (Filer)

    2/27/26 5:05:19 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACMR
    $ACOR
    $ADPT
    $AFMD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 8, 2023 - FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

    For Immediate Release: December 08, 2023 Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signali

    12/8/23 11:12:21 AM ET
    $BLUE
    $VRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    August 17, 2022 - FDA Approves First Cell-Based Gene Therapy to Treat Adult and Pediatric Patients with Beta-thalassemia Who Require Regular Blood Transfusions

    For Immediate Release: August 17, 2022 Today, the U.S. Food and Drug Administration approved Zynteglo (betibeglogene autotemcel), the first cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions.  “Today’s approval is an important advance in the treatment of beta-thalassemia, particularly in individuals who require ongoing

    8/17/22 2:12:27 PM ET
    $BLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    February 18, 2022 - FDA Alerts the Public to Potentially Contaminated Products from Family Dollar Stores in Six States

    For Immediate Release: February 18, 2022 Today, the U.S. Food and Drug Administration is alerting the public that several categories of FDA-regulated products purchased from Jan. 1, 2021, through the present from Family Dollar stores in Alabama, Arkansas, Louisiana, Mississippi, Missouri and Tennessee may be unsafe for consumers to use. The impacted products originated from the company’s distribution facility in

    2/18/22 8:06:10 PM ET
    $ARVL
    Auto Manufacturing
    Consumer Discretionary

    $ACMR
    $ACOR
    $ADPT
    $AFMD
    Leadership Updates

    Live Leadership Updates

    View All

    AMG Appoints G. Staley Cates to its Board of Directors

    Karen L. Alvingham to Retire from Board of Directors  WEST PALM BEACH, Fla., Feb. 26, 2026 (GLOBE NEWSWIRE) -- AMG, a strategic partner to leading independent investment management firms globally, today announced the appointment of G. Staley Cates to its Board of Directors (the "Board"), effective April 1, 2026; the Company also announced the forthcoming retirement of Karen L. Alvingham from the Board, effective April 1, 2026. Lady Alvingham was appointed to AMG's Board of Directors in January 2018. Mr. Cates served as the Vice Chairman of Southeastern Asset Management, Inc. ("Southeastern"), an independent global investment management firm, from 2015 through 2024, having served as Presi

    2/26/26 6:59:00 AM ET
    $AMG
    Investment Managers
    Finance

    Viatris Appoints Matthew J. Maletta as Chief Legal Officer

    Brian Roman to Leave the Company After More Than 20 Years of Exemplary Service; Will Remain Advisor Through Transition Period  PITTSBURGH, Feb. 3, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) announced today that Matthew J. Maletta has been appointed Chief Legal Officer (CLO), effective February 9, 2026. The appointment follows the transition of the Company's current CLO, Brian Roman, after more than 20 years of exemplary service to Viatris and its predecessor company, Mylan. Roman, who has served in multiple leadership positions and played a key role in supporting the Company's operations, portfolio and growth initiatives, will stay on through April 1, 2026, to ensure a smooth transition

    2/3/26 8:30:00 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era

    VANCOUVER, British Columbia, Jan. 14, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary – The global immuno-oncology market is set to explode from its current $35 billion level to a massive $185.69 billion by 2035 as the industry moves toward the coordinated activation of the immune system[1]. This surge is being accelerated by the $69.16 billion genomics revolution, which is now integrating advanced profiling into every oncology workflow to pick winning treatments[2]. This strategic push for registration-ready precision assets fuels the 2026 investment case for Oncolytics Biotech Inc. (NASDAQ:ONCY), ImmunityBio (NASDAQ:IBRX), OS Therapies (NYSE-A: OSTX), BioNTech SE (NASDAQ:BNTX),

    1/14/26 10:39:59 AM ET
    $BNTX
    $CMPX
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ACMR
    $ACOR
    $ADPT
    $AFMD
    Financials

    Live finance-specific insights

    View All

    Ritchie Bros. Sells US$265+ Million in Orlando and Delivers Unmatched Scale at Industry's Largest Auction

    14,500+ assets sold as global event signals strong start to 2026 equipment market RB Global, Inc. (NYSE:RBA) (TSX:RBA), a trusted global marketplace for insights, services and transaction solutions for commercial assets and vehicles, today announced Ritchie Bros. Auctioneers generated more than US$265+ million in gross transaction value (GTV) during its Feb. 16-20 premier global auction in Orlando, FL, selling more than 14,500 equipment items, trucks and vehicles. The five-day auction drew more than 19,500 participants from 80+ countries across construction, transportation, agriculture and energy sectors. Approximately 86% of assets sold to U.S. buyers, including 39% purchased by Florid

    2/26/26 4:45:00 PM ET
    $RBA
    Real Estate

    ACM Research Reports Fourth Quarter and Fiscal Year 2025 Results

    FREMONT, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- ACM Research, Inc. ("ACM") (NASDAQ:ACMR), a leading supplier of wafer processing solutions for semiconductor and advanced packaging applications, today reported financial results for its fourth quarter and fiscal year ended December 31, 2025. "2025 was a year of strong execution for ACM," said ACM's President and Chief Executive Officer, Dr. David Wang. "We delivered record annual revenue of $901 million, up 15% year over year, outperforming estimated China WFE. We strengthened our foundation for long-term growth by advancing new products, expanding our global production capacity, and enhancing global funding initiatives." Dr. Wang conti

    2/26/26 7:00:00 AM ET
    $ACMR
    Industrial Machinery/Components
    Technology

    Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results

    Reports Fourth-Quarter Total Revenues of $3.7B and Full-Year 2025 Total Revenues of $14.3BMeets or Exceeds 2025 Financial Guidance Across All Key Metrics[1]Returns More Than $1B to Shareholders in 2025; Expects Balanced Capital Allocation Approach for 2026Provides 2026 Financial Guidance; Positioned for Sustainable GrowthAnticipates Regulatory Decisions for Six Product Candidates in 2026 and Multiple Important Pipeline MilestonesCompletes Enterprise-Wide Strategic Review; Expects to Deliver $650M in Total Cost Savings With Reinvestment of up to $250M Over the Next 3 YearsPITTSBURGH, Feb. 26, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today announced robust financial results for the four

    2/26/26 6:59:00 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACMR
    $ACOR
    $ADPT
    $AFMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Monopar Therapeutics Inc.

    SC 13D/A - Monopar Therapeutics (0001645469) (Subject)

    12/17/24 5:01:42 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Carvana Co.

    SC 13D/A - CARVANA CO. (0001690820) (Subject)

    12/16/24 6:13:26 PM ET
    $CVNA
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by Arqit Quantum Inc.

    SC 13D/A - Arqit Quantum Inc. (0001859690) (Subject)

    12/13/24 8:03:28 PM ET
    $ARQQ
    Computer Software: Prepackaged Software
    Technology

    $ACMR
    $ACOR
    $ADPT
    $AFMD
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Does the Recent Purchase at Monopar Therapeutics Inc. on Jun 21 Indicate?

    Monopar Therapeutics Inc. has recently seen notable insider activity, with Chief Operating Officer Cittadine Andrew purchasing $25,574 worth of shares on June 21st, 2024. This purchase, comprising 32,508 units at $0.79, increased Cittadine's direct ownership by 21% to 186,132 units as reported in the SEC Form 4. When analyzing this transaction alongside other recent insider activities within the company, interesting patterns and trends start to emerge. Looking back, Cittadine Andrew has been consistently adding to his position in Monopar Therapeutics Inc. over the past few months, showcasing a strong conviction in the company's future prospects. On May 31st, Cittadine Andrew made a substan

    6/22/24 8:00:00 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    What Led to the Purchase at Aerovate Therapeutics Inc. on Jun 20?

    Recently, on June 20, 2024, a notable insider purchase was made at Aerovate Therapeutics Inc. Director Ra Capital Management, L.P. bought $1,549,944 worth of shares, acquiring 928,110 units at $1.67 per share as reported in the SEC Form 4. Insider transactions like these are closely watched by investors as they can provide valuable insights into the company's prospects. When analyzing insider transactions, it is essential to look for patterns and trends among multiple transactions to gauge the overall sentiment within the company. Several other SEC Form 4 filings were made around the same time, on June 7, 2024, by various insiders at Aerovate Therapeutics Inc. These included transactions by

    6/21/24 3:23:59 PM ET
    $AVTE
    Biotechnology: Pharmaceutical Preparations
    Health Care